Stocks Clock Fourth...
Health Care: Drugs
Pfizer Inc (PFE: NYSE)
$28.96 0.00 | 0.00%
05/20/13 - 10:10 AM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with PFE
- Portfolio NameUser Type
- Userdennis diamonds
- Userchrisnash69 Portfolio 1
- Userdennis all star
- UserBUYS
- UserThe Best Dividend Stocks
- ContributorHigh Volume Technicals for ...
- ContributorHigh Volume Technicals for ...
- UserFitz.ColinGerald
- ContributorHigh Volume Technicals for ...
- ContributorDividend Stocks for the Wee...
Latest PFE Headlines from TheStreet
- Pfizer Reaches New 52-Week High (PFE) 04.19.13 | 04:04 pm
- This Rally Is in Make-or-Break Mode: 5 Must-See Charts 04.18.13 | 12:04 pm
- 5 Stocks Pulling The Health Care Sector Downward 04.17.13 | 01:04 pm
- Pfizer Inc Stock Buy Recommendation Reiterated (PFE) 04.16.13 | 10:04 am
- 'Mad Money' Uncovered: Big Pharma on a Down Day in the Market 04.15.13 | 01:04 pm
- Dow Today: Pfizer (PFE) Lower 04.15.13 | 01:04 pm
- Mad Money Uncovered: Merck and the Pharma Laggards
04.15.13 | 12:04 pm - Expect More Dividend Increases Like P&G 04.15.13 | 11:04 am
- Cramer's Top Stock Picks: FRT PFE K GIS 04.13.13 | 06:04 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan 04.12.13 | 08:04 pm
Press Releases for PFE
- Pharmaceutical Companies, Investor Coalition Develop Industry Standard-Setting Principles For Recoupment Policies Covering Major Compliance Failures - PR Newswire 04.04.13 | 08:04 am
- Pfizer’s BOSULIF® (bosutinib) Receives Conditional Marketing Authorization From The European Commission - Business Wire 03.28.13 | 03:03 am
- Pfizer Invites Public To View And Listen To Webcast Of April 30 Conference Call With Analysts - Business Wire 03.26.13 | 10:03 am
- XELJANZ® (tofacitinib Citrate) Approved In Japan For The Treatment Of Adults With Rheumatoid Arthritis (RA) - Business Wire 03.25.13 | 07:03 am
- New Trial Results Support Treatment With Inspra (eplerenone) Within First 24 Hours Of Symptoms, In Addition To Standard Therapy, In Patients With Acute STEMI Without Heart Failure. - Business Wire 03.10.13 | 02:03 pm
- United States Patent & Trademark Office Grants Pfizer Reissue Patent For Celebrex® (celecoxib Capsules) - Business Wire 03.05.13 | 09:03 am
- Pfizer Presents Phase 3 Safety And Immunogenicity Data On Prevnar 13® In Adults With HIV - Business Wire 03.04.13 | 04:03 pm
- Top-Line Data Show Lyrica Met Primary Endpoint In Clinical Trial As Adjunctive Therapy Versus Levetiracetam In Patients With Partial Onset Seizures - Business Wire 02.21.13 | 08:02 am
- Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference - Business Wire 02.19.13 | 11:02 am
- Pfizer Inc. Issues Statement On ZoetisTM IPO - Business Wire 02.01.13 | 09:02 am
Partner Headlines for PFE
- Companies slide $181B through tax loopholes - MSN Money 04.19.13 | 10:04 am
- Thursday's BioPharma Trade Movers - Seeking Alpha 04.18.13 | 09:04 am
- Questcor Pharmaceuticals, Inc. (QCOR) Ex-Dividend Date Scheduled for April 18, 2013 - NASDAQ 04.17.13 | 01:04 pm
- Cyclacel Pharmaceuticals, Inc. (CYCCP) Ex-Dividend Date Scheduled for April 17, 2013 - NASDAQ 04.16.13 | 01:04 pm
- Stocks Off Lows, Trade Mixed; Gold, Oil And Silver Unravel - Investor's Business Daily 04.15.13 | 12:04 pm
- Needed: Cure for soaring cost of medical school - MSN Money 04.15.13 | 12:04 am
- Pfizer’s Big Breakthrough for Breast Cancer - Wall St. Cheat Sheet 04.13.13 | 05:04 am
- Two drug giants spending less to woo doctors - MSN Money 04.12.13 | 01:04 pm
- Market Close Report: NASDAQ Composite index closes at 3,300.16 up 2.91 points - NASDAQ 04.11.13 | 08:04 pm
- Parexel Grows Earnings With Big Pharma Partnerships - Investor's Business Daily 04.04.13 | 02:04 pm
